WebApr 8, 2024 · Morè and colleagues report an extensive review of the current main topics concerning multiple myeloma, accurately describing the therapeutic novelties currently in various stages of development and discussing the most recent evidence presented in the literature (even ASH 2024 and over). The paper is thorough and well-described. WebSep 10, 2024 · The field of myeloma treatment in refractory or relapsed patients after standard therapy entered a new era due to the B-cell maturation antigen (BMCA) targeted approach. BCMA is a member of the tumor necrosis factor receptor family with high expression in mature B-lymphocytes and plasma cells.
Protracted viral infections in patients with multiple myeloma …
WebDec 14, 2024 · Treatments for myeloma Standard treatment options include: Targeted therapy. Targeted drug treatments focus on specific weaknesses present within cancer cells. By blocking these … WebTeclistamab can be used to treat multiple myeloma that no longer responds to at least 4 other myeloma drugs, including proteasome inhibitors, immunomodulatory drugs, and a monoclonal antibody to CD38. This drug is given as an IV infusion, typically once a week. Common side effects of teclistamab include: Fever; Feeling very tired; Headache ... clas ohlson headset
BiTE – The Next Innovative Treatment in Lymphoma and Myeloma?
WebApr 14, 2024 · Isatuximab-irfc is an antibody treatment that targets CD38, a protein on some blood cancer cells. The therapy was previously approved in combination with pomalidomide (Pomalyst) and dexamethasone for … WebJun 7, 2024 · Novel immunotherapies, such as CAR T cell therapy (CAR) and bispecific T cell engagers (BiTE), are intensively targeting different surface antigens, such as BMCA, … WebAMG 420, a bispecific T-cell engager targeting B-cell maturation antigen, may be a safe and effective treatment for patients with relapsed/refractory multiple myeloma. In a phase … clas ohlson hageby norrköping